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Benzodiazepines, including diazepam (DZP), loraze-pam (LZP), and midazolam (MDZ), are considered
the initial drugs of choice for status epilepticus (SE) treat-
ment. A number of trials have demonstrated their safety
and efficacy; however, the failure rate ranges from 10% to
55%.1,2 This may be attributable, in part, to suboptimal
benzodiazepine dosing and timing of administration.
The Neurocritical Care Society (NCS) and Ameri-
can Epilepsy Society (AES) have published evidence-
based guidelines for benzodiazepine use in SE that
specify drugs, doses, and routes of administration.1,2
Initial benzodiazepine treatment should consist of
either a 10-mg dose of intramuscular (IM) MDZ for
patients weighing > 40 kg or 5 mg for those 13 to 40
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kg or intravenous (IV) LZP 0.1 mg/kg/dose (maxi-
mum 4 mg/dose) or IV DZP 0.15 to 0.2 mg/kg/dose
(maximum 10 mg/dose).1,2 The LZP and DZP doses
can be repeated if the initial dose fails to stop the sei-
zure. Although not included in the guidelines, based
on pharmacokinetics, 10 mg IV MDZ dose can be
considered adequate therapy.3
Reports have documented underdosing of benzodi-
azepines used in SE; however, comprehensive informa-
tion regarding patient age, setting, drugs, doses, timing
of doses, and routes is limited.4,5 This report describes
patterns of benzodiazepine use in SE in a geographi-
cally diverse population.
The Established Status Epilepticus Treatment Trial
(ESETT) provided an opportunity to systematically
observe benzodiazepine administration in patients sub-
sequently determined to have SE unresponsive to ben-
zodiazepines.6 Using preenrollment data from ESETT
subjects, we describe benzodiazepine treatment with
respect to: 1) drug choice, dose, and route of adminis-
tration; 2) timing and setting in which the drugs were
administered; and 3) patient weight (< 40 or ≥ 40 kg
for LZP, ≤ 40 or > 40 kg for MDZ, and < 66.7 or
≥ 66.7 kg for DZP). NCS and AES guidelines were
used to define underdosing for our analyses. These
weight-based cutoffs were per published guidelines.1,2
Because patients could receive more than one benzo-
diazepine, the cumulative dose was determined using
LZP equivalents to account for differences in drug
potencies. Transmucosal benzodiazepines, e.g., rectal
DZP or intranasal/buccal MDZ, given prior to emer-
gency medical services (EMS) arrival are included in the
calculation of cumulative benzodiazepine dose. For
patients weighing ≥ 32 kg, 10 mg MDZ or DZP was
considered equal to 4 mg LZP.1,2 For patients weigh-
ing < 32 kg, 0.3 mg/kg DZP IV or 0.2 mg/kg MDZ
IV or 0.3 mg/kg MDZ IM were considered equal to
0.1 mg/kg LZP IV.1,2 There was no upper limit for the
benzodiazepine dose required to qualify for ESETT
enrollment. While the ESETT protocol stipulated a
minimum cumulative adequate dose for enrollment
(Data Supplement S1, available as supporting informa-
tion in the online version of this paper, which is avail-
able at http://onlinelibrary.wiley.com/doi/10.1111/ace
m.13811/full), instructions on the rate and frequency
of dosing were not provided. ESETT sites were
expected to dose benzodiazepines as per their local stan-
dards of care. The settings in which benzodiazepines
were administered were categorized as: 1) prior to EMS,
2) EMS, and 3) emergency department (ED).
Data were collected from subjects enrolled at 41
U.S. academic and community hospitals. For this
analysis, the ESETT database was frozen on December
12, 2016. Data were analyzed using SAS version 9.4
to compute descriptive statistics.
This analysis included 207 ESETT subjects: 88
children, 95 adults aged 18–65, and 24 older adults
aged ≥ 66 (Data Supplement S1). There were 511
administrations with an average (mean  SD) of
2.47  1.04 doses per subject. LZP comprised 61%
of doses, followed by MDZ (31%) and DZP (8%).
Most DZP doses (65%) were given prior to EMS arri-
val, whereas 68% of MDZ doses were given by EMS
personnel, and 94% of LZP doses were administered
in the ED. A comparison of routes of administration
reveals that 95% of LZP doses were administered IV,
while 5% (N = 17) were by IM, IN, or buccal routes.
With regard to MDZ, 41% of doses were given IM,
45% were by the IV route, and the remaining 14%
by IN or buccal routes. The rectal route was used for
69% of DZP administrations. Of these, 78% and
96% were in patients younger than 12 and 18 years,
respectively.
FIRST DOSE OF FIRST BENZODIAZEPINE
Among all subjects, 102 received their first dose of
any benzodiazepine in the ED. Overall, 29.8% of first
doses met minimum recommendations per guidelines.
Of these, 86.7% of DZP, 14.5% of MDZ, and 23.2%
of LZP administrations met the minimum dose recom-
mendations. Figure 1 shows that for subjects < 40 kg
the guideline recommended LZP (≥ 0.1 mg/kg) or
MDZ (≥ 5 mg) dose was administered as a first dose
in 41.9 and 12.5% of the cases, respectively. In con-
trast, for those weighing ≥ 40 kg the recommended
LZP (≥ 4 mg) or MDZ (≥ 10 mg) dose was adminis-
tered in 14.7 and 15.4% of the subjects, respectively.
A DZP dose ≥ 10 mg was administered in 60% of the
subjects ≥ 66.7 kg, while 96% of DZP administrations
were ≥ 0.15 mg/kg in those < 66.7 kg.
DOSE PER ADMINISTRATION
Seventy-seven percent of DZP, 10.7% of MDZ, and
21.8% of LZP doses administered were at or above the
recommendations (Data Supplement S1). Prior to
EMS, most administrations were DZP (25/37) given
at or above the minimum recommended doses,
whereas in both the EMS and the ED settings, most
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of the administered benzodiazepine doses were below
recommendations.
CUMULATIVE BENZODIAZEPINE DOSES
Cumulative dosing patterns were examined using LZP
equivalents (Data Supplement S1). Among 138 adults
and older children weighing ≥ 32 kg, the cumulative
dose in LZP equivalents was < 4 mg in 9%, 4 mg in
42%, 5 to 6 mg in 25%, and > 7 mg in 24%. In 68 chil-
dren weighing < 32 kg, the cumulative dose was < 0.1
mg/kg in 18%, 0.1 to < 0.2 mg/kg in 44%, 0.2 to < 0.3
mg/kg in 28%, and >0.3 mg/kg in 10% of subjects.
The results of this study suggest that many patients
with SE who fail benzodiazepine treatment are not
receiving recommended initial doses of benzodiazepines.
The observed practice was not consistent with published
evidence-based guidelines, which stipulate that the initial
treatment of SE begin with a benzodiazepine adminis-
tered as early as possible, as a single full dose, and by an
appropriate route.1,2 In contrast, we found a pattern of
administering multiple, small doses with approximately
70% of patients receiving a lower than guideline recom-
mended first dose of the first drug. If, however, rectal
DZP is excluded, the first doses of MDZ and LZP, mostly
administered by EMS and/or ED personnel, were below
guideline recommendations 80% of the time. Adminis-
tration of subsequent doses continued the pattern of
underdosing. Regardless of the number of administra-
tions, approximately 12% of patients never received the
required cumulative dose needed to meet ESETT eligi-
bility criteria. This potentially reduced response to
Figure 1 Distribution of first dose of the first administered benzodiazepine (DZP, MDZ or LZP) as actual doses. (Top panel) Fixed dosing;
(bottom panel) weight-based dosing. (A) DZP doses for those ≥ 66.7 kg (IV) or ≥ 50 kg (rectal); (B) MDZ doses for those > 40 kg; (C) LZP
doses for those ≥ 40 kg; (D) DZP doses for those < 66.7 kg (IV) or < 50 kg (rectal); (E) MDZ doses for those ≤ 40 kg; (F) LZP doses for
those < 40 kg. Categorized as met (blue) or did not meet (red) guidelines. DZP = diazepam; LZP = lorazepam; MDZ = midazolam.
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benzodiazepines as delay in administering appropriate
therapy is thought to place patients at risk for longer sei-
zures and poor outcomes.7
Our results extend the findings from earlier reports
on initial management of SE.4,5 In a multicenter study
of adults, the investigators found that > 80% of
patients with SE received a lower than recommended
LZP dose.4 Langer and Fountain,5 in a retrospective
study of generalized convulsive SE in 170 children and
adults, found that only 11% of the patients, all chil-
dren, received an adequate initial benzodiazepine dose.
The problem of benzodiazepine underdosing in SE
may be attributable to the perceived risk of cardiorespi-
ratory compromise associated with benzodiazepines.8
However, Alldredge et al.8 showed that the rate of res-
piratory or circulatory complications was nearly dou-
bled (p = 0.08) in untreated SE patients versus those
treated with benzodiazepines. We also noted that on
17 occasions LZP was administered by IM, IN, or buc-
cal routes. These routes do not support rapid LZP
absorption and are inappropriate for SE therapy.9
Our analysis is limited to SE patients who continued to
have seizures despite benzodiazepine treatment. Since initial
benzodiazepine underdosing is likely associated with treat-
ment failure, our population may overestimate the rate of
underdosing among patients treated for SE. While this lim-
its the generalizability of our findings, benzodiazepine
underdosing is particularly important in this subpopulation
in whom seizures continue and may progress to refractory
SE with attendant high rates of morbidity and mortality.
Conversely, this analysis may underestimate the rate of
underdosing because only those given an adequate cumula-
tive benzodiazepine dose were eligible for ESETT enroll-
ment. It is possible that eagerness to enroll subjects could
bias toward lower cumulative benzodiazepine doses. How-
ever, in this scenario, EDs would be more likely to adminis-
ter larger individual doses to meet the minimum adequate
dose sooner and should not affect EMS practice. Lastly our
sample size precluded the analysis of specific factors such as
regional effects on dosing patterns.
Benzodiazepine underdosing for the treatment of SE
was common in this geographically diverse set of EDs.
This phenomenon may contribute to decreased effi-
cacy. Further, the low doses used per administration in
both ED and EMS settings suggests this represents
practice culture rather than an artifact in practice dri-
ven by study enrollment. Hence, greater educational
efforts and overcoming systematic and structural barri-
ers are needed to change clinical practice.
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